atenolol has been researched along with Metabolic Diseases in 2 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We assessed adverse metabolic effects of atenolol and hydrochlorothiazide among hypertensive patients with and without abdominal obesity using data from a randomized, open-label study of hypertensive patients without evidence of cardiovascular disease or diabetes mellitus." | 5.14 | Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. ( Beitelshees, AL; Boerwinkle, E; Chapman, AB; Cooper-DeHoff, RM; Gong, Y; Gums, JG; Hall, K; Johnson, JA; Parekh, V; Turner, ST; Wen, S; Zineh, I, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manrique, C | 1 |
| Johnson, M | 1 |
| Sowers, JR | 1 |
| Cooper-DeHoff, RM | 1 |
| Wen, S | 1 |
| Beitelshees, AL | 1 |
| Zineh, I | 1 |
| Gums, JG | 1 |
| Turner, ST | 1 |
| Gong, Y | 1 |
| Hall, K | 1 |
| Parekh, V | 1 |
| Chapman, AB | 1 |
| Boerwinkle, E | 1 |
| Johnson, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)[NCT00246519] | Phase 4 | 1,701 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00246519)
Timeframe: baseline to 18 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Atenolol +HCTZ Arm | -12.06 |
| HCTZ + Atenolol | -13.33 |
1 trial available for atenolol and Metabolic Diseases
| Article | Year |
|---|---|
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Diabetes Mellitus; Drug Therapy, Combina | 2010 |
1 other study available for atenolol and Metabolic Diseases
| Article | Year |
|---|---|
Thiazide diuretics alone or with beta-blockers impair glucose metabolism in hypertensive patients with abdominal obesity.
Topics: Adrenergic beta-Antagonists; Atenolol; Diabetes Mellitus; Diuretics; Drug Therapy, Combination; Fast | 2010 |